Last mentioned: Mar 21, 2026
Market Correction
Nasdaq and S&P 500 hit six-month lows amid escalating conflict in the Gulf.
AACR Presentation Announcement
Zymeworks confirms multiple data sessions for Ziihera at the upcoming annual meeting.
Sector Watchlists
Key 'Worth Watching' reports published for both Biotech and VR sectors.
Meta Strategy Shift
Meta announces the shutdown of Horizon Worlds on Meta Quest devices.
VR Research Phase
Market analysts release multiple reports highlighting VR stocks for research.
Regulatory Progress
Advancement of Biologics License Application (BLA) filings for lead indications.
ASCO Data Release
Positive pivotal Phase 2 results in biliary tract cancer (BTC) showcased at ASCO.
As major indices hit six-month lows due to geopolitical conflict, specialized reports highlight resilient opportunities in biotechnology and virtual reality. These sectors are navigating a complex landscape of clinical breakthroughs and strategic shifts, including Meta's retreat from its core metaverse platform.
Zymeworks Inc. has announced a series of clinical and preclinical presentations for its lead asset, Ziihera® (zanidatamab-hrii), at the 2026 AACR Annual Meeting. The data will highlight the therapeutic potential of this HER2-targeted bispecific antibody across multiple oncology indications.